ADVANCED FINANCIAL

STATEMENT ANALYSIS
Selecting a Pharmaceutical Company from
Northeast Asia for Investment

Submitted By-
Akshay Surana – 18PGDM002
Jasmeet Singh – 18PGDM022
Parth Hrishi Sharma – 18PGDM028
Shubham Chhajer – 18PGDM046
Priya Harlalka – 18PGDM084
 SINOVAC BIOTECH COMPANY LTD.
RISK ASSOCIATED: HIGH
• Growth Potential of the company
 Revenue increased by 440% from 2005-08
 Gross Profit increased by 484% in the same period
 Net income increased by 257% during the period
 The cash in hand has increased from 347% from $7.35mn to $32.89mn

• Growth Potential in China

 40% of potential market in Pharmaceutical market of China is unexplored

• Inventory Turnover is Low

 TAKEDA PHARMACEUTICAL COMPANY LTD.
RISK ASSOCIATED: MODERATE
• Wide market reach due to its presence in more than 10 countries
• High Share in the market
• Increase in revenue but the rate of increment in last 4 years is been only 15.43%
• Growth in Net Income
• Increased in R&D expenditure despite stringent government policies
Q. What factors other than financial analysis needs to be
consider while selecting the analysis for investment?

• Growth of Pharmaceutical market

• Over the Counter (OTC) and Prescribed drug market
• Untapped market where investment is to be made
• Information of the competitors in the market
• Awareness of the drug
• Competitors in the market
• Government policy